TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female patients 16-70 years of age (inclusive)~* Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) \[performed locally\]. All sickle cell disease genotypes are eligible.~* Experienced at least 1 VOC within the preceding 12 months prior to Screening, as determined by medical history.~* If receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to Screening~* Hemoglobin ≥4.0 g/dL. Absolute neutrophil count ≥1.0 x 109/L and platelet count ≥75 x 109/L~* Adequate renal and hepatic function as defined:~* GFR ≥45 mL/min/1.73 m2 calculated by CKD-EPI~* ALT ≤3 x ULN~* Direct (conjugated) bilirubin ≤2 x ULN~* ECOG performance status ≤2~* Written informed consent (or assent/ parental consent for minor subjects) prior to any screening procedures~Exclusion Criteria:~* History of stem cell transplant.~* Acute VOC ending 7 days prior to first dosing~* Ongoing hospitalization prior to Screening~* Received blood products within 30 days to first dosing~* Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)~* History of severe hypersensitivity reactions to other monoclonal antibodies~* Received a monoclonal antibody or immunoglobulin -based agent within 1 year of Screening, or has documented immunogenicity to a prior biologic.~* Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to Screening~* Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)~* Resting QTcF ≥470 msec at pretreatment (baseline) or other cardiac or cardiac repolarization abnormality

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- crizanlizumab (Type: EXPERIMENTAL): SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children ≥6 and ≤14 years of age~2. Enrolled in one of the selected primary schools in the region~3. Infected with schistosomiasis (i.e. Schistosoma spp. eggs in urine and/or stool)~4. Informed consent from parents/guardians signed~Exclusion Criteria:~1. History of, or ongoing, epilepsy or psychiatric illness (I.e. recent history of depression, generalized anxiety disorder; history of psychosis, schizophrenia or other major psychiatric disorders) or known hypersensitivity to one of the three study drugs~2. Chronic medication for any reason~3. Any severe underlying illness, including severe malnutrition or severe chronic schistosomiasis, based on clinical judgement~4. Any febrile illness~5. Exposure to PZQ or ACT within the three previous months.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Praziquantel (Type: ACTIVE_COMPARATOR): Participants in this arm will receive one dose of PZQ at baseline at 40 mg/kg.
- Artesunate-Mefloquine (Type: EXPERIMENTAL): Participants in this arm will receive the Artesunate-Mefloquine (fixed-drug)combination at 4 mg/kg artesunate and 8 mg/kg mefloquine at 3 consecutive days. This will be repeated twice; at week 6 and week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Understand the study procedures and provide written informed consent before any assessment is performed.~* Subjects diagnosed with Cocaine Use Disorder according to DSM 5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Ed.).~* Must use cocaine through snorting (intranasally) as primary route of administration.~* Recent cocaine use confirmed by positive urine screen for 1 or more benzoylecgonine (BE).~* Must be seeking treatment for cocaine dependence and have a desire to reduce or cease cocaine use.~Exclusion Criteria:~* Has current diagnosis of Substance Use Disorder (according to the DSM 5) on alcohol, cannabis or other stimulants, except cocaine.~* Meets current or lifetime DSM 5 criteria for schizophrenia or any psychotic disorder, or organic mental disorder.~* Have current treatment for Substance Use Disorder (e.g.: disulfiram, acamprosate, methyl phenidate, modafinil, topiramate, immediate release dexamfetamine,or baclofen).~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test~* Have a history of any illness, condition, and use of medications that in the opinion of the investigator or designee might confound the results of the study or pose additional risk in administering the investigational agents to the subject or preclude successful completion of the study~* Current or/and previous treatment with concomitant medications that are strong or moderate inducers/inhibitors of CYP3A4 (e.g., clarithromycin, ketoconazole, ritonavir, etc.)~* History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.~* Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).~* Score yes on item 4 or item 5 of the Suicidal Ideation section of the CSSRS, if this ideation occurred in the past 6 months, or yes on any item of the Suicidal Behavior section, except for the Non-Suicidal Self-Injurious Behavior (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.~* Controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching tablet of placebo taken orally BID
- AFQ056 (Type: EXPERIMENTAL): Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer.~* Received ≥2 prior platinum-based treatment regimens including platinum based regimen that must have been administered immediately prior to maintenance therapy in this trial.~* Received no more than 1 non-platinum chemotherapy regimen. Prior hormonal therapy will not be counted as a non-platinum regimen.~* Must have had at least a 6-month disease-free period following prior treatment with the penultimate platinum-based chemotherapy and achieved a response.~* For the last chemotherapy course prior to study entry, patients must have received a platinum-based doublet chemotherapy regimen and have achieved a CR or PR (as defined by RECIST) and/or a GCIG CA-125 response.~* Have sufficient archival tumor tissue for analysis.~Exclusion Criteria:~* History of prior cancer except for non-melanoma skin cancer, breast cancer curatively \> 3 years ago, curatively treated solid tumor (\>5 years ago without evidence of recurrence), and synchronous endometrial cancer (Stage 1A) with ovarian cancer.~* Prior treatment with any PARP inhibitor, including rucaparib. Patients who received prior iniparib are eligible.~* Untreated or symptomatic central nervous system metastases.~* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of study drug.~* Required drainage of ascites during the final 2 cycles of their last platinum-based regimen and/or during the period between the last dose of chemotherapy of that regimen and randomization to maintenance treatment in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
- Placebo (Type: PLACEBO_COMPARATOR): Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with de novo heart Failure and LVEF \<= 40% admitted in hospital, without contraindications for BB prescription with cardiologist up-titration prescription and without having achieved BB target dose previous discharge and signing informed consent.~Exclusion Criteria:~* Contraindications for BB.~* Living in a nursing home.~* Life expectancy \< 6 months.~* Unable to self-care or mental disease without caregiver.~* Unable to weight~* Without phone~* Unable to go to clinic visit.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heart Failure (HF) cardiologist up-titration (Type: ACTIVE_COMPARATOR): Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
- HF nurse up-titration (Type: EXPERIMENTAL): Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has been diagnosed with type 2 diabetes mellitus~* Has a hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at study start~* Has a body mass index (BMI)of 25 kg/m2 to 45 kg/m2, inclusive, at study start~* Has been on a stable treatment regimen of metformin for a minimum of 2 months prior to study start~* Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:~  1. Hormone replacement therapy (female subjects)~ 2. Oral contraceptives (female subjects)~ 3. Antihypertensive agents~ 4. Lipid-lowering agents~ 5. Thyroid replacement therapy~ 6. Antidepressant agents~ 7. Drugs known to affect body weight, including prescription medications (e.g. orlistat \[XENICAL®\], sibutramine \[MERIDIA®\], topiramate \[TOPAMAX®\]) and over-the-counter antiobesity agents~Exclusion Criteria:~* Has been previously exposed to exenatide once weekly~* Has donated blood within 60 days of study start or is planning to donate blood during the study~* Currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:~  1. Exenatide (BYETTA®) or any Dipeptidyl peptidase-4 DPP-4)inhibitor, sulfonylurea (SU), thiazolidinedione (TZD), or glucagon-like peptide (GLP)-1 analog within 3 months prior to study start~ 2. Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of study start~ 3. Insulin within 2 weeks of study start or for more than 1 week within 3 months of study start~ 4. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption~ 5. Drugs interacting with the CYP2C8 enzyme system, including gemfibrozil (LOPID®) and rifampin~* Has received any investigational drug within 1 month (or five half-lives of investigational drug, whichever is greater) of study start~* Has previously experienced a clinically significant adverse event (e.g., significant edema) related to TZD or DPP-4 inhibitor use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed stage IV melanoma~  * Stage M1a, M1b, or M1c~ * Mucosal, ocular, or unknown primary melanoma~* Previously untreated OR received up to 3 prior systemic therapy regimens (excluding vaccine therapy) for metastatic disease~* Plasma basic fibroblast growth factor level at least 15 pg/mL~* Measurable or evaluable disease~* Central nervous system (CNS) involvement allowed provided CNS directed therapy has been given and disease has been clinically stable for ≥ 3 months~  * Brain computed tomography (CT) scan or Magnetic resonance imaging (MRI) to confirm stable disease required ≤ 4 weeks prior to study entry~* Age: 18 and over~* ECOG Performance status of 0-2~* Life expectancy at least 6 months~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8 g/dL (transfusions allowed)~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* Alanine Aminotransferase (ALT) no greater than 2 times ULN~* Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min~* At least 4 weeks since prior interferon in the adjuvant or metastatic setting~* At least 4 weeks since prior chemotherapy in the adjuvant or metastatic setting~* At least 4 weeks since prior endocrine therapy in the adjuvant or metastatic setting~* At least 4 weeks since prior radiotherapy in the adjuvant or metastatic setting~* At least 4 weeks since prior surgery in the adjuvant or metastatic setting~* At least 4 weeks since other prior therapy in the adjuvant or metastatic setting~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Myocardial infarction within the past 6 months~* Other active malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Other concurrent illness that would preclude study participation~* History of severe depression~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG-interferon alfa-2b (Type: EXPERIMENTAL): Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy males~2. Body mass index (BMI) =18.5 to =29.9 kg/m2~Exclusion criteria:~1. Any clinically relevant abnormal finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance~2. Any evidence of a clinically relevant previous or concomitant disease as judged by the investigator.~3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency Virus, Hepatitis B and Hepatitis C testing is required for participation.~4. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)~5. Intake of prescribed or over-the-counter drugs with a long half-life (\>24 hours) within at least one month or less than 5 half-lives of the respective drug prior to administration or during the trial~6. Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)~7. Inability to refrain from smoking during days of confinement at the study center~8. Alcohol abuse (average more than 30 g/day)~9. Current drug abuse

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 695501 (Type: EXPERIMENTAL): Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
- adalimumab - US (Type: ACTIVE_COMPARATOR): Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
- adalimumab - EU (Type: ACTIVE_COMPARATOR): Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months~* Written informed consent~Exclusion Criteria:~* Legal age limitations (country specific)~* Indication for anticoagulation other than PE or DVT~* Creatinine clearance (CLcr) \<10 mL/min, severe hepatic disease, or bacterial endocarditis~* Participation in a pharmacotherapeutic study other than the Van Gogh-PE or DVT study within the prior 30 days~* Life expectancy \<3 months~* Patients in whom anticoagulation treatment for their index PE or DVT should be continued beyond 6 months~* Active bleeding or high risk for bleeding~* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg or diastolic blood pressure \> 110 mm Hg~* Pregnancy, or childbearing potential without proper contraceptive measures, women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented stable Coronary Artery Disease (stable angina, previous MI history, previous history of revascularization);~* Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception~Exclusion Criteria:~* History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or Coronary Artery Bypass Graft (CABG))~* History of liver or kidney disease~* Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma~* History of intolerance or allergy to Aspirin or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Aspirin + Placebo
- 2 (Type: ACTIVE_COMPARATOR): Aspirin + clopidogrel
- 3 (Type: EXPERIMENTAL): Aspirin + Ticagrelor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete